MAZE Maze Therapeutics, Inc.
MAZE Maze Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $26.57 · VWAP $32.37 · -15.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, President + 2 others sold $2.9M, Aug 31–Sep 8
Coverage
1 watchlist
MAZE Price Structure
Loading timeframes…
Peers
Every watchlist MAZE belongs to, members best 30-day change first — MAZE highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.76, net income -$45M (SEC filing). Across the print the stock moved +1.3% (close before → first close after).
full note →Against street estimates
How MAZE's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about MAZE from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 25 days ago · Sep 22
- Maze Therapeutics Inc Stock Price Today | NASDAQ: MAZE Live - Investing.com
- Maze Therapeutics, Inc. (MAZE) Earnings Call Transcript & Summary
- Maze Therapeutics Earnings: $495M Cash, Expected 2029 Runway | MAZE Stock News
- Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Maze Therapeutics
- Maze Therapeutics, Inc. Common Stock (MAZE) Live Share Price, Invest From India
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
MAZE research tape
19 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.